Dimerix's (ASX:DXB) potential access to $50 million in non-dilutive funding could lead to it having up to AU$96.6 million in combined cash and non-dilutive funding available, which would be sufficient to fully fund the ongoing phase three trial and dispel any near-term capital raising risk, Euroz Hartleys said in a note on Thursday.

It indicated this would not be traditional debt funding, but is rather repayable from future milestone payments and/or royalties.

The commercial opportunity remains significant and unchanged, Euroz Hartleys added.

The investment firm maintained its speculative buy rating on Dimerix with a price target of AU$1.35 per share.